People: Johnson & Johnson (JNJ)
18 Jan 2017
Dr. Paulus A. Stoffels is Chief Scientific Officer, Worldwide Chairman - Pharmaceuticals Group of Johnson & Johnson. He joined the Company in 2002 with the acquisition of Virco and Tibotec, where he was Chief Executive Officer of Virco and Chairman of Tibotec. In 2005, he was appointed Company Group Chairman, Global Virology where he led the development of PREZISTA® and INTELENCE®, leading products for the treatment of HIV. In 2006, he assumed the role of Company Group Chairman, Pharmaceuticals, with responsibility for worldwide research and development for the Central Nervous System and Internal Medicine Franchises. Dr. Stoffels was appointed Global Head, Research & Development, Pharmaceuticals, in 2009, and in 2011 became Worldwide Chairman, Pharmaceuticals, with responsibility for the Company's therapeutic pipeline through global research and development and strategic business development. In 2012, Dr. Stoffels was also appointed Chief Scientific Officer, with responsibility for enterprise-wide innovation and product safety, and a Member of the Executive Committee. He Provided strong leadership within the Pharmaceutical Research & Development organization, as evidenced by the significant growth of our Pharmaceutical pipeline.
|Total Annual Compensation, USD||3,330,480|
|Restricted Stock Awards, USD||4,208,870|
|Long-Term Incentive Plans, USD||--|
|All Other, USD||3,246,390|
|Fiscal Year Total, USD||10,785,700|